Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 659

Sort by

Sort Order Select

Journal Articles

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Estelle Bourbon, Maël Heiblig, Mathieu Gerfaud Valentin, Thomas Barba, Cécile-Audrey Durel, Jean Christophe Lega, Fiorenza Barraco, Pascal Sève, Yvan Jamilloux, Pierre Sujobert

Blood (2021) 137 (26): 3682–3684.

https://doi.org/10.1182/blood.2020010177

Published: 2021

Includes: Supplemental data

Journal Articles

Single-Cell RNA Sequencing Reveals a Distinct Transcriptome Signature of Hematopoiesis in GATA2 Deficiency

Zhijie Wu, MD PhD, Shouguo Gao, PhD, Sachiko Kajigaya, PhD, Jinguo Chen, PhD, Rongye Shi, BS, Carrie Diamond, MD, Cindy Palmer, BSN, Amy P. Hsu, Katherine R. Calvo, MD PhD, Dennis D. Hickstein, MD, Steven M. Holland, MD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 3735.

https://doi.org/10.1182/blood-2019-124774

Published: 2019

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

Marlie H Fisher, Greg Kirkpatrick, PhD, Courtney L Jones, PhD, Brett M. Stevens, PhD, Michael Callaghan, MD, Eric Pietras, PhD, Kenneth L. Jones, PhD, Christopher C. Porter, MD, Jorge Di Paola, MD

Blood (2019) 134 (Supplement_1): 2316.

https://doi.org/10.1182/blood-2019-132032

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Lacey S. Williams, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 5697.

https://doi.org/10.1182/blood-2019-122932

Published: 2019

Journal Articles

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Andrew Doyle, MBBS, BSc, FRPATH, Karen Breen, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia, Beverley J. Hunt, Gavin Ling, MBBS, BSc, FRCPath, Claire N Harrison, Professor, Natalia Curto Garcia, MD MBBS

Blood (2019) 134 (Supplement_1): 4183.

https://doi.org/10.1182/blood-2019-128170

Published: 2019

Journal Articles

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

Diego V Clé, MD PhD, Luiz Fernando Catto, MD, Luiz Guilherme Darrigo, PhD, Elvis Valera, Fernanda Gutierrez-Rodrigues, PhD, Flavia S. Donaires, PhD, André Pinto, Renan C. Albino, Bárbara Santana, Jose Baddini-Martinez, MD PhD, Rodrigo T. Calado, MD PhD

Blood (2019) 134 (Supplement_1): 2501.

https://doi.org/10.1182/blood-2019-130844

Published: 2019

Journal Articles

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Christina A. Snider, BA, Kevin Fung, Francesca Gould, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Hassan Awada, MD, Milo Co, Teodora Kuzmanovic, BA, Bhumika J. Patel, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 2696.

https://doi.org/10.1182/blood-2019-126311

Published: 2019

Journal Articles

Loss-of-Function and Gain-of-Function Consequences of GATA2 Disease Mutations

Koichi Ricardo Katsumura, MD PhD, Peng Liu, PhD, Charu Mehta, MS, Kyle J Hewitt, PhD, Alexandra Soukup, PhD, Isabela J Fraga de Andrade, Bachelors in Biological Science, Erik A. Ranheim, MD PhD, Kirby D Johnson, PhD, Emery H Bresnick, PhD

Blood (2019) 134 (Supplement_1): 2519.

https://doi.org/10.1182/blood-2019-129447

Published: 2019

Journal Articles

Recurrent Gene Mutations in Pediatric Patients with AML By Targeted Sequencing ―the Jccg Study, JPLSG AML-05―

Blood (2019) 134 (Supplement_1): 2697.

https://doi.org/10.1182/blood-2019-126545

Published: 2019

Journal Articles

Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival

Constance Baer, PhD, Wencke Walter, PhD, Anna Stengel, PhD, Stephan Hutter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 2735.

https://doi.org/10.1182/blood-2019-128234

Published: 2019

Journal Articles

Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia

Mindy P Kresch, BS, Wenbin Xiao, MD PhD, Kamal Menghrajani, MD, Christopher Famulare, MS, Minal A Patel, MPH, Jeeyeon Baik, Mikhail Roshal, MD PhD, Ross L. Levine, MD, Martin S. Tallman, MD, Jacob L Glass, MD PhD

Blood (2019) 134 (Supplement_1): 2718.

https://doi.org/10.1182/blood-2019-131104

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation

Mitsutaka Nishimoto, MD PhD, Ke Zeng, MD PhD, Meixian Huang, Mi-Ae Lyu, PhD, Nina D. Shah, MD, Swaminathan P. Iyer, MD, Robert Z. Orlowski, MD, PhD, Simrit Parmar, MBBS

Blood (2019) 134 (Supplement_1): 3095.

https://doi.org/10.1182/blood-2019-128418

Published: 2019

Journal Articles

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Guldane Cengiz Seval, Isinsu Kuzu, Seher Yuksel, Gulsah Kaygusuz, Klara Dalva, MD, Muhit Ozcan, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 3197.

https://doi.org/10.1182/blood-2019-127541

Published: 2019

Journal Articles

Identification of Recurrent Alternative RNA Splicing in Adverse-Risk Acute Myeloid Leukemia

Govardhan Anande, Ashwin Unnikrishnan, PhD, Nandan Deshpande, PhD, Sylvain Mareschal, Aarif M. N. Batcha, Tobias Herold, MD, Sören Lehmann, MD PhD, Marc Wilkins, PhD, Jason Wong, PhD, John Pimanda, MBBS, PhD

Blood (2019) 134 (Supplement_1): 457.

https://doi.org/10.1182/blood-2019-129537

Published: 2019

Journal Articles

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Theodore Braun, MD PhD, Cody Coblentz, Sarah A Carratt, PhD BS, Mariam Okhovat, PhD, Amy Foley, MEng., Zachary Schonrock, BS, Kimberly Nevonen, Rhonda E. Ries, MA, Shannon K. McWeeney, PhD, Claus Nerlov, PhD, Soheil Meshinchi, MD PhD, Lucia Carbone, PhD, Brian J. Druker, Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 543.

https://doi.org/10.1182/blood-2019-124773

Published: 2019

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Single-Cell RNA Sequencing Reveals a Distinct Transcriptome Signature of Hematopoiesis in GATA2 Deficiency

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Loss-of-Function and Gain-of-Function Consequences of GATA2 Disease Mutations

Recurrent Gene Mutations in Pediatric Patients with AML By Targeted Sequencing ―the Jccg Study, JPLSG AML-05―

Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival

Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Identification of Recurrent Alternative RNA Splicing in Adverse-Risk Acute Myeloid Leukemia

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only